Attached files
| file | filename |
|---|---|
| 8-K - HI TECH PHARMACAL CO INC | v182554_8k.htm |
| EX-99.1 - HI TECH PHARMACAL CO INC | v182554_ex99-1.htm |
Exhibit
99.2 April 28, 2010 Press Release
Hi-Tech
Pharmacal Announces the Hiring of Kamel Egbaria, Ph.D. as Chief Scientific
Officer
AMITYVILLE,
N.Y. April 28, 2010—Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty
pharmaceuticals company, announced today that Kamel Egbaria, Ph.D. has joined the Company
as Chief Scientific Officer.
Mr.
Egbaria has over 25 years of experience in pharmaceutical management and
research. He joins Hi-Tech Pharmacal from Qualitest Pharmaceuticals,
where he served most recently as Chief Scientific Officer and Vice President of
Research and Development. During his six year career with Qualitest
Pharmaceuticals he was responsible for Research and Development and Regulatory
Affairs.
David
Seltzer, President and CEO commented: "We welcome Kamel to our management team
and believe that his experience will help Hi-Tech Pharmacal grow and achieve
continued success."
Mr.
Egbaria earned a Ph.D. in Pharmaceutics from Hebrew University in Jerusalem,
Israel.
About
Hi-Tech Pharmacal
Hi-Tech
Pharmacal is a specialty pharmaceutical company developing, manufacturing and
marketing generic and branded products. The Company specializes in difficult to
manufacture liquid and semi-solid dosage forms and produces a range of sterile
ophthalmic, otic and inhalation products. The Company's Health Care Products
Division is a leading developer and marketer of branded prescription and OTC
products for the diabetes marketplace. Hi-Tech's ECR Pharmaceuticals subsidiary
markets branded prescription products.
Forward-looking
statements (statements which are not historical facts) in this Press Release are
made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not promises or guarantees
and investors are cautioned that all forward-looking statements involve risks
and uncertainties, including but not limited to the impact of competitive
products and pricing, product demand and market acceptance, new product
development, the regulatory environment, including without limitation, reliance
on key strategic alliances, availability of raw materials, fluctuations in
operating results and other results and other risks detailed from time to time
in the Company's filings with the Securities and Exchange Commission. These
statements are based on management's current expectations and are naturally
subject to uncertainty and changes in circumstances. We caution you not to place
undue reliance upon any such forward looking statements which speak only as of
the date made. Hi-Tech is under no obligation to, and expressly disclaims any
such obligation to, update or alter its forward-looking statements, whether as a
result of new information, future events or otherwise.
SOURCE:
Hi-Tech Pharmacal Co., Inc.
Hi-Tech
Pharmacal Co., Inc.
Bill
Peters, 631-789-8228